Adnan Khosravi
Overview
Explore the profile of Adnan Khosravi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
278
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Seifi S, Esfahanimonfared Z, Khosravi A, Moeini Nia F
Cureus
. 2025 Jan;
16(12):e75710.
PMID: 39811219
Introduction Despite the favorable prognosis of Hodgkin's disease (HD), some patients experience disease recurrence. Therefore, determining recurrence prognostic factors is very crucial to identify patients at risk of early relapse,...
2.
Salimi B, Seifi S, Khosravi A, Shiari S, Moradi R, Daneshfard B, et al.
Arch Iran Med
. 2024 Oct;
27(9):501-507.
PMID: 39465525
Background: Lung cancer (LC) is one of the leading causes of cancer-related deaths worldwide. In Iran, it is the second most common cause of cancer-related deaths for men and the...
3.
Jahani M, Mashayekhi P, Omrani M, Khosravi A, Ali D, Azad Manjiri S, et al.
Iran Biomed J
. 2024 Sep;
28(4):208-15.
PMID: 39289877
Background: Early and minimally invasive detection of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) patients is a promising tool to select patients for targeted therapy...
4.
Seifi S, Fakhrai G, Esfahani-Monfared Z, Khosravi A, Abedini A, Salimi B, et al.
Tanaffos
. 2024 Aug;
22(4):411-417.
PMID: 39176146
Background: Lung cancer is the leading cause of cancer death. Among different lung cancer histopathologies, small cell lung cancer (SCLC) has been known to be the most aggressive and lethal...
5.
Mirtavoos-Mahyari H, Abbasi Dezfouli A, Esfahani-Monfared Z, Khosravi A, Seifi S, Sheikhy K
Tanaffos
. 2023 Apr;
21(3):376-383.
PMID: 37025321
Background: Activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to tyrosine kinase inhibitors (TKIs), but responses to TKIs is not permanent and drug resistance eventually happens...
6.
Najmi K, Emami H, Seifi S, Khosravi A, Ilbeigi A, Mortezaee V, et al.
Tanaffos
. 2023 Mar;
21(2):201-206.
PMID: 36879740
Background: Cancer is one of the leading causes of morbidity and mortality around the world. Caregivers of these patients are affected by various physical, emotional, social, spiritual, and financial factors...
7.
Seifi S, Salimi B, Monfared Z, Sabahi C, Kafi H, Khosravi A
J Pharm Policy Pract
. 2023 Jan;
16(1):16.
PMID: 36698207
Background: Lung cancer is the leading cause of cancer deaths worldwide in both men and women, and non-small cell lung cancer (NSCLC) accounts for the majority (~ 85%) of lung...
8.
Allahyari A, Ehsanpour A, Najafi B, Ansarinejad N, Mehrzad V, Kalantari B, et al.
BMC Cancer
. 2022 Dec;
22(1):1348.
PMID: 36550442
No abstract available.
9.
Allahyari A, Ehsanpour A, Najafi B, Ansarinejad N, Mehrzad V, Kalantari B, et al.
BMC Cancer
. 2022 Sep;
22(1):960.
PMID: 36071409
Background: Breast cancer is the most frequently diagnosed cancer and the leading reason for cancer-related death among women. Neoadjuvant treatment with dual-HER2 (human epidermal growth factor receptor 2) blockade has...
10.
Jenabian A, Ehsanpour A, Mortazavizadeh S, Raafat J, Razavi M, Khosravi A, et al.
Support Care Cancer
. 2022 Jul;
30(10):8151-8158.
PMID: 35792924
Purpose: Phase IV clinical trials are required to evaluate the real-world safety and effectiveness of drugs. This study aimed to evaluate the safety and effectiveness of once-per-cycle administration of PegaGen...